Cresemba holds seven patents in total, and none are expired yet. Generic versions of Cresemba could start to become available from 14 March 2028, following the expiry of the last patent. However, drug patent challenges can be made against Cresemba from 2026-09-06.
Cresemba is primarily used to treat invasive aspergillosis and invasive mucormycosis, two serious infections caused by fungi. The active ingredient, isavuconazonium sulfate, works by stopping the growth of fungus.
Cresemba has a total of seven patents, with the last one expiring on 14 March 2028. Key patents include ones for N-substituted carbamoyloxyalkyl-azolium derivatives and active ingredient containing stabilised solid forms. Keep a lookout for Cresemba generic versions from 2028. Below are the details of the patent: